Overall, our findings propose SSR2 and UBE2D3 as candidate diagnostic and prognostic biomarkers, providing a hypothesis-generating framework for developing targeted therapeutic strategies against HBV-HCC. Here, UBE2D3 is linked to hepatocellular carcinoma.